Research reveals a defect in myosin binding to TNFR2-M196R causes TNF-independent proinflammatory activity. The ability to genotype this polymorphism should help to predict inadequate responders to anti-TNF therapies early on, and allowing a personalized approach to the treatment of rheumatoid and psoriatic diseases.
TNFi-Induced Psoriasis and Idiopathic Psoriasis Can Be Distinguished on Biopsy
Is it idiopathic psoriasis or TNFi-induced psoriasis? A new study finds histological differences between these two types of psoriatic lesions that impact treatment.
PROMIS Measures Are Associated with Disease Activity in Psoriatic Arthritis
Clinical disease activity measures provide only a limited assessment of health domains that are important to patients, which may lead to under- or over-treatment and patient dissatisfaction. Rheumatologist Elaine Husni, MD, MPH, explains the findings of her recent study, and why it’s so important for clinicians to listen carefully when patients report symptoms.
Targeting Tumor Necrosis Factor Pathways in Psoriatic Diseases: The Next Step
Preclinical models suggest that specific blockade of TNFR2 may significantly reduce inflammation and ameliorate signs of psoriatic diseases, while maintaining normal immune response in the host, including the ability to combat infection and cancer. In this article, M. Elaine Husni, MD, MPH, highlights her latest research and discusses her plans to use her new R01 grant to continue her translational work.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
A DISCONNECT Among Rheumatologists, Dermatologists and Patients
The DISCONNECT study assessed differing perceptions among patients and physician specialists regarding symptoms associated with psoriatic disease.
PON1 Activity Correlates with Systemic Inflammation, Disease Activity and CV Risk in PsA
A recent Cleveland Clinic study determined that paraoxonase-1 (PON1) has the potential for use as a biomarker for cardiac risk in psoriatic disease.
The Psychosocial Burden of Psoriatic Arthritis
With a wealth of assessment tools at the rheumatologist’s disposal, a collaborative approach involving primary care, dermatology and behavioral health will allow the best assessment and treatment of psychosocial burden in patients with PsA.
Basic and Clinical Immunology Online Boot Camp
If it’s been a while since you last worked your way through basic and clinical immunologic principles as they apply to diagnosis, treatment and pathogenesis of autoimmune and autoinflammatory diseases, Clinical Immunology Boot Camp is for you.
Patient, Provider Awareness of Elevated Risk of Cardiovascular Disease in Psoriatic Arthritis
Enhanced protocols for CVD risk assessment as well as more comprehensive research regarding CVD in PsA are urgently needed.
Asymmetric Dimethylarginine as a Novel Biomarker for Cardiovascular Risk in Psoriatic Diseases
Our laboratory tests whether aberrant levels of plasma and tissue L-arginine metabolites serve as an early, non-invasive predictor of CV disease in psoriatic patients.